Hostname: page-component-84b7d79bbc-x5cpj Total loading time: 0 Render date: 2024-07-26T11:52:49.888Z Has data issue: false hasContentIssue false
  • English
  • Français

Successful use of oral prostaglandin E1 derivative for maintaining ductus-dependent systemic circulation in a neonate with trisomy 18

Part of: Basic Science

Published online by Cambridge University Press:  22 August 2019

Akiko Miyake ,
Seigo Okada Open the ORCID record for Seigo Okada [Opens in a new window]  and
Yuichi Ishikawa
Akiko Miyake
Affiliation:
Department of Pediatrics, Saiseikai Shimonoseki General Hospital, Shimonoseki, Yamaguchi, Japan
Seigo Okada*
Affiliation:
Department of Pediatrics, Saiseikai Shimonoseki General Hospital, Shimonoseki, Yamaguchi, Japan
Yuichi Ishikawa
Affiliation:
Department of Pediatrics, Saiseikai Shimonoseki General Hospital, Shimonoseki, Yamaguchi, Japan
*
Author for correspondence: S. Okada, MD, PhD, Department of Pediatrics, Saiseikai Shimonoseki General Hospital, 8-5-1, Yasuoka, Shimonoseki, Yamaguchi 759-6603, Japan. Tel: 81-83-262-2300; Fax: 81-83-262-2301; E-mail: sokada0901@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

A Japanese female infant with trisomy 18 was diagnosed with hypoplastic left heart syndrome variant. She was administered oral prostaglandin E1 every 6 hours through a feeding tube as an alternative drug for lipo-prostaglandin E1. Oral prostaglandin E1 was effective for maintenance of the ductus arteriosus and may serve as a palliative treatment approach.

Keywords

Chromosomal disorderCHDpalliative treatmentpatent ductus arteriosus
Type
Brief Report
Information
Cardiology in the Young , Volume 29 , Issue 9 , September 2019 , pp. 1222 - 1224
Copyright
© Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Muneuchi, J, Yamamoto, J, Takahashi, Y, et al. Outcomes of cardiac surgery in trisomy 18 patients. Cardiol Young 2011; 21: 209–215.CrossRefGoogle ScholarPubMed
Kosiv, KA, Gossett, JM, Bai, S, Collins, RT 2nd. Congenital heart surgery on in-hospital mortality in trisomy 13 and 18. Pediatrics 2017; 140: e20170772.CrossRefGoogle ScholarPubMed
Peterson, JK, Kochilas, LK, Catton, KG, Moller, JH, Setty, SP. Long-term outcomes of children with trisomy 13 and 18 after congenital heart disease interventions. Ann Thorac Surg 2017; 103: 1941–1949.CrossRefGoogle ScholarPubMed
Janvier, A, Farlow, B, Barrington, KJ. Parental hopes, interventions, and survival of neonates with trisomy 13 and trisomy 18. Am J Med Genet C Semin Med Genet 2016; 172: 279–287.CrossRefGoogle ScholarPubMed
Akkinapally, S, Hundalani, SG, Kulkarni, M, et al. Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions. Cochrane Database Syst Rev 2018; 2: CD011417.Google ScholarPubMed
Morita, TO, Yamaguchi, A, Kimura, S, et al. Stability of lenalidomide suspension after preparation by a simple suspension method for enteral tube administration. J Oncol Pharm Pract 2016; 22: 579–583.CrossRefGoogle ScholarPubMed
Silove, ED, Roberts, DG, de Giovanni, JV. Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease. Arch Dis Child 1985; 60: 1025–1030.CrossRefGoogle ScholarPubMed
Saji, T, Matsuura, H, Hoshino, K, Yamamoto, S, Ishikita, T, Matsuo, N. Oral prostaglandin E1 derivative (OP-1206) in an infant with double outlet right ventricle and pulmonary stenosis. Effect on ductus-dependent pulmonary circulation. Jpn Heart J 1991; 32: 735–740.CrossRefGoogle Scholar
Ruiz Rubio, JL, Hernández, M, Rivera de los Arcos L, Martínez AC, García-Sacristán A, Prieto D. Mechanisms of prostaglandin E1-induced relaxation in penile resistance arteries. J Urol 2004; 171: 968–973.CrossRefGoogle ScholarPubMed
Matsuura, H, Saji, T, Yamamoto, S, Ishikita, T, Aoki, Y, Matsuo, N. Dilation of the ductus arteriosus by oral prostaglandin E1 derivative in cyanotic congenital heart diseases. Am Heart J 1993; 125: 1453–1454.CrossRefGoogle ScholarPubMed